Abortion Drug RU-486 vs. Breast Cancer
Drug's Progesterone-Blocking Ability Prevents Breast Cancer in Mice
WebMD News Archive
Nov. 30, 2006 -- The abortion drug RU-486 prevents breast cancer in mice
carrying a dangerous "cancer gene" mutation, new studies show.
RU-486 itself will not be the answer for women; the potent drug is not meant
for long-term uses such as cancer prevention.
But scientists say the cancer-preventing effects of RU-486 stem from the
drug's ability to block progesterone, a major sex hormone.
So new, safer progesterone-blocking drugs are on the way to treat women with
the BRCA1 gene mutations linked to breast cancer, says Eva Y.-H. P. Lee, PhD,
professor of biological chemistry and cell biology at the University of
"To prevent cancer, many women who are BRCA1 carriers have very
traumatic surgery -- their ovaries and both breasts are removed," Lee tells
"Many of these women have asked us about clinical use of RU-486, but it
would have too many side effects for prevention use," she says.
"However, I am happy to say that for the past three years there have been
companies working on more appropriate anti-progesterone drugs."
Lee and colleagues report their findings in the Dec. 1 issue of
How BRCA1 Causes Cancer
Breast cancer strikes between 36% and 85% of women with mutations in the
BRCA1 gene, or in a second gene, BRCA2. These women also face a 16% to 60%
chance of ovarian
Every cell in the body carries BRCA1 genes, which are involved in DNA
It has never been clear why mutant, inactive versions of the gene are linked
mostly to breast and ovarian cancer.
Lee's team found that mouse and human breast cells with BRCA1 mutations are
overly sensitive to progesterone, a major sex hormone. Indeed, mice with BRCA1
mutations get breast cancer.
But when Lee and colleagues gave the mice RU-486, the animals did not get
The researchers are now testing new progesterone-blocking drugs to see if
they have the same effect in mice.
These are exciting findings.
But researchers can cure many kinds of cancers in mice, notes Kristin A.
Skinner, MD, director of the multidisciplinary breast program and chief of
surgical oncology at the University of Rochester in New York.